Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. - Wikidata - awgldk - TriplyDB

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

http://www.wikidata.org/entity/Q37017110

about

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel.

P2860

Q28078111-DD862142-3C6D-43ED-BD98-EC19DEF4D897 Q48087890-2F567B0F-A8A6-444C-BA75-431CE054AD91

P2860

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

http://www.wikidata.org/entity/Q37017110

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@en

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@nl

type

label

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@en

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@nl

prefLabel

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@en

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@nl

P1433

Q37017110-3162A01A-B1B1-48DF-BCBD-02B4085C3992

P1476

Q37017110-901BC21F-0B63-4685-A487-E4DF7BBC3C5E

P2093

Q37017110-6AFF9BD2-821A-434B-8018-E7E17E2DE89F

Q37017110-85249C02-7652-4672-BB1B-20F7CC32AC73

Q37017110-FA2D7E09-BE5A-4A04-8E40-2ACDB270B0DD

P2860

Q37017110-000D18B1-3F9C-44BE-9F73-B1B5641F2B0F

Q37017110-017B8220-EF0A-4C6F-A202-78563DD40592

Q37017110-0547F31D-06D9-45B9-87E1-5D50671BDE19

Q37017110-05C20C89-3CD2-4F5C-918B-FA1D14263BB4

Q37017110-0894885F-A134-4018-AB51-C334B68648EC

Q37017110-0A01E0F4-4D3F-44B4-BE5D-2A0E7FE9B498

Q37017110-0F0E8649-94C5-4A0D-B449-7D677D3270DD

Q37017110-1310B76C-0D9A-4AEE-B895-D720ADFAEE49

Q37017110-136F3996-8204-43D0-8336-CABCB5CFE8CF

Q37017110-15BFCF39-4CAC-4C4B-A1FD-2F9267BC7188

P2888

Q37017110-6695104B-0CEB-4418-B927-929D53798DBB

P304

Q37017110-F0AC1120-16B0-4F05-B66E-6268433A5F1D

P31

Q37017110-095BFA63-A890-4B3D-90AF-2B701698AC0D

P356

Q37017110-A3E9B23F-CD4C-4EF9-94CC-3743A10DB1ED

P433

Q37017110-B84E5909-FD3E-4FD9-9D28-7BB495251C4A

P478

Q37017110-1C54C73E-E8F5-431B-BBF3-2C79296943F4

P50

Q37017110-07D38E7C-52AE-4DA6-B832-EFCB12218215

Q37017110-7D4A8F6C-B489-46CC-B277-6BB2FDC9BEA7

Q37017110-B846A95E-54FB-4E89-912B-3B2A88D97A6F

P577

Q37017110-21FCABB3-EDC1-4B8E-8CCB-B778F5B04710

P698

Q37017110-CC50F386-42D2-4031-94CB-052ED7ED39AE

P921

Q37017110-E4DF947F-695D-407B-9797-8788FF8F2828

P932

Q37017110-1AB3722C-A757-4E81-A911-6AF5122DD1BE

P356

S10555-016-9602-8

P1433

Cancer and Metastasis Reviews

P1476

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

@en

P2093

Jason K Sicklick

http://www.w3.org/2001/XMLSchema#string

Kelly Shimabukuro

http://www.w3.org/2001/XMLSchema#string

Paul T Fanta

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

P2888

s10555-016-9602-8

P304

263-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-016-9602-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

P577

2016-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26857926

http://www.w3.org/2001/XMLSchema#string

P921

P932

4912391

http://www.w3.org/2001/XMLSchema#string